T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alcon
ALC
|
+$2.11B |
| 2 |
Linde
LIN
|
+$1.34B |
| 3 |
American International
AIG
|
+$1.34B |
| 4 |
Marvell Technology
MRVL
|
+$1.28B |
| 5 |
TSS
Total System Services, Inc.
TSS
|
+$1.24B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$2.27B |
| 2 |
Eli Lilly
LLY
|
+$1.64B |
| 3 |
NVIDIA
NVDA
|
+$1.59B |
| 4 |
RHT
Red Hat Inc
RHT
|
+$1.55B |
| 5 |
Booking.com
BKNG
|
+$1.12B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.88% |
| 2 | Healthcare | 16.96% |
| 3 | Financials | 13.79% |
| 4 | Consumer Discretionary | 13.57% |
| 5 | Industrials | 9.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1026
Wendy's
WEN
$1.64B
| $31.6M | ﹤0.01% |
1,612,184
+1,502,470
| +1,369% | +$28.3M |
|
|
HI
1027
DELISTED
Hillenbrand
HI
| $31.5M | ﹤0.01% |
797,303
-8,002
| -1% | -$321K |
|
1028
NewMarket
NEU
$8.66B
| $31.5M | ﹤0.01% |
78,680
+11,878
| +18% | +$4.91M |
|
|
RAVN
1029
DELISTED
Raven Industries Inc
RAVN
| $31.5M | ﹤0.01% |
877,033
-352,162
| -29% | -$12.9M |
|
1030
CytomX Therapeutics
CTMX
$736M
| $31.4M | ﹤0.01% |
2,800,872
-289,801
| -9% | -$3.04M |
|
|
PCSB
1031
DELISTED
PCSB Financial Corporation
PCSB
| $31.3M | ﹤0.01% |
1,547,625
+39,896
| +3% | +$773K |
|
|
DTV
1032
DELISTED
DTE Energy Company 2016 Corporate Units
DTV
| $31.2M | ﹤0.01% |
556,505
-596,939
| -52% | -$33.3M |
|
1033
Labcorp
LH
$26.1B
| $31.2M | ﹤0.01% |
209,933
+109
| +0.1% | +$15.2K |
|
1034
Utah Medical Products
UTMD
$228M
| $31.2M | ﹤0.01% |
325,664
+9,510
| +3% | +$801K |
|
1035
Cirrus Logic
CRUS
$6.12B
| $30.9M | ﹤0.01% |
707,238
-392
| -0.1% | -$17K |
|
1036
Coty
COTY
$2.44B
| $30.8M | ﹤0.01% |
2,300,142
-3,302,524
| -59% | -$40.6M |
|
1037
lululemon athletica
LULU
$13.6B
| $30.7M | ﹤0.01% |
170,509
+16,730
| +11% | +$2.91M |
|
|
PRNB
1038
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
| $30.6M | ﹤0.01% |
922,952
+8,970
| +1% | +$280K |
|
1039
Hercules Capital
HTGC
$3.13B
| $30.6M | ﹤0.01% |
2,388,538
-235,397
| -9% | -$3.05M |
|
|
ALLK
1040
DELISTED
Allakos
ALLK
| $30.6M | ﹤0.01% |
706,359
-60,126
| -8% | -$2.47M |
|
1041
CMS Energy
CMS
$22.1B
| $30.6M | ﹤0.01% |
528,412
-332,422
| -39% | -$18.7M |
|
1042
Advanced Energy
AEIS
$13.6B
| $30.6M | ﹤0.01% |
543,353
+15,658
| +3% | +$839K |
|
1043
Culp Inc
CULP
$43.9M
| $30.5M | ﹤0.01% |
1,606,921
-16,678
| -1% | -$318K |
|
1044
Henry Schein
HSIC
$10B
| $30.4M | ﹤0.01% |
435,167
-349,233
| -45% | -$23.1M |
|
1045
National Vision
EYE
$1.58B
| $30.2M | ﹤0.01% |
983,059
-2,878,890
| -75% | -$82.5M |
|
1046
Jazz Pharmaceuticals
JAZZ
$16B
| $30.1M | ﹤0.01% |
211,312
-1,991
| -0.9% | -$268K |
|
1047
Viatris
VTRS
$18.7B
| $30.1M | ﹤0.01% |
1,581,174
-182,361
| -10% | -$4.03M |
|
|
CBM
1048
DELISTED
Cambrex Corporation
CBM
| $30.1M | ﹤0.01% |
642,151
-1,912
| -0.3% | -$80.2K |
|
|
SFIX
1049
Stitch Fix
SFIX
$484M
| $30M | ﹤0.01% |
938,242
-372,360
| -28% | -$9.99M |
|
|
RWT
1050
Redwood Trust
RWT
$598M
| $30M | ﹤0.01% |
1,812,349
-66,784
| -4% | -$1.08M |
|
Similar funds
T. Rowe Price Associates's Q2 2019 Portfolio in Review
As of Q2 2019, T. Rowe Price Associates held 2,600 positions worth $712B, up 4.7% from $680B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
T. Rowe Price Associates's Q2 2019 filing shows 72 new, 1,394 increased, 949 reduced and 59 closed positions. Its largest new stake was Alcon: 36,020,796 shares worth $2.23B. The largest sale was UnitedHealth, an estimated $2.27B.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 18% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q2 2019 buy was Alcon: 36,020,796 shares worth $2.23B.
- T. Rowe Price Associates added most to Linde in Q2 2019, an estimated $1.34B increase.
- T. Rowe Price Associates's biggest Q2 2019 reduction was UnitedHealth, cutting an estimated $2.27B.
- T. Rowe Price Associates fully exited Ultimate Software Group Inc in Q2 2019, selling an estimated $609M.
- T. Rowe Price Associates's ten largest holdings make up 21% of its $712B portfolio in Q2 2019.
- T. Rowe Price Associates opened 72 new positions and closed 59 in Q2 2019.
- T. Rowe Price Associates's portfolio value rose 4.7% quarter-over-quarter to $712B.
Based on T. Rowe Price Associates's 13F filing for Q2 2019, filed 15 Aug 2019.